| Name | Title | Contact Details |
|---|---|---|
Shashi Vangala |
Chief Data Analytics and Value Creation Officer | Profile |
Thomas Marlow |
Chief Information Officer | Profile |
Guess & Co. Corporation revitalizes and serves rural communities and neighboring urban communities through technology, real estate, energy, and health care solutions, along with providing diversified solutions to meet the needs of our clients. We work with communities, small businesses, corporations, and governments looking to grow and expand leveraging our solutions. Guess & Co. believes in the power of Rural America and the potential for meaningful partnerships between rural and neighboring urban communities that benefit the United States of America. We are committed to using our resources to build bridges of cooperation and support between rural and neighboring urban communities that strengthen our country. Our objective is to positively impact 100 million lives by 2032 through access, empowerment, economic development, and support through the solutions that we provide to clients. We align ourselves with others who are just as passionate about making lives better through technology, real estate, energy, health care and diversified solutions as we are. From our headquarters in Overland Park, Kansas we deliver solutions to clients in rural and neighboring urban communities. While we are based in the Midwestern region of the United States, our strategic footprint includes over 20 states throughout the country setup to meet the needs of clients. Our core businesses are technology, real estate, energy, and health care solutions. We also serve clients through our diversified solutions which range from consulting to commercial funding.
American Health Fitness Center is a Fort Wayne, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
Global company delivering innovation-led strategy, technology, and business consulting services